TY - JOUR T1 - Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma JF - In Vivo JO - In Vivo SP - 2821 LP - 2828 DO - 10.21873/invivo.12108 VL - 34 IS - 5 AU - YASUKATA OHASHI AU - MEGUMI YATABE AU - DAISUKE NIIJIMA AU - KENTARO TANI AU - CHIAKI OGAWA AU - YUTAKA YACHI AU - TOSHIYA KAGOO AU - SAIGEN BOKU AU - HIRONORI UENO AU - TAKAHIRO YANO AU - KOJI HIGAI AU - AKIHIRO YOKOYAMA Y1 - 2020/09/01 UR - http://iv.iiarjournals.org/content/34/5/2821.abstract N2 - Background/Aim: Gastrointestinal toxicity is common in patients receiving common therapy of ixazomib with lenalidomide and low-dose dexamethasone (IRd) for relapsed/refractory multiple myeloma. Here, we investigated the safety and effectiveness of ixazomib dosing schedules. Patients and Methods: We retrospectively evaluated 17 consecutive patients treated with IRd (10 patients on ixazomib dose-escalation strategy (2.3 mg starting dose); seven patients on standard dose). Results: The incidence of grade 3 or more haematological and grade 2 or more non-haematological adverse events was lower in the dose-escalation group than in the standard-dose group, and only that of diarrhoea was significantly lower. The median time to treatment interruption was significantly longer in the dose-escalation group than in the standard-dose group. There was no significant difference in the overall response rate (20% vs. 43%) and disease control rate (70% vs. 86%). Conclusion: A dose-escalation strategy to optimise ixazomib dosing may reduce treatment interruption due to adverse events without compromising its antitumor activity. ER -